Please login to the form below

Not currently logged in
Email:
Password:

melanoma

This page shows the latest melanoma news and features for those working in and with pharma, biotech and healthcare.

Roche’s Tecentriq combo scores FDA approval for melanoma

Roche’s Tecentriq combo scores FDA approval for melanoma

Tecentriq, plus MEK inhibitor Cotellic (cobimetinib) and BRAF inhibitor Zelboraf (vemurafenib), has been backed for the treatment of BRAF V600 mutation-positive advanced melanoma patients. ... The FDA approval of this Tecentriq combination represents an

Latest news

More from news
Approximately 82 fully matching, plus 289 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 17 partially matching documents found.

Latest appointments

  • Industry appointments Industry appointments

    Most recently, Hassan built the oncology-focused biology, preclinical and biomarker units for Immunocore, overseeing early development and the first-in-human trial of a TCR based biologic targeting a melanoma

  • Packer Forbes appoints Jade McCudden Packer Forbes appoints Jade McCudden

    McCudden has worked across a number of disease areas including hepatitis C, anticoagulation, Alzheimer's disease, women's health, melanoma and nicotine replacement therapy.

  • Array appoints Victor Sandor chief medical officer Array appoints Victor Sandor chief medical officer

    This includes the Colorado, US-based company's binimetinic, a MEK inhibitor in phase III trials for ovarian cancer and melanoma, and filanesib, a KSP inhibitor for multiple myeloma.

  • Bruno Strigini leaves Merck & Co for Novartis Bruno Strigini leaves Merck & Co for Novartis

    Leading the field though is Strigini's former company Merck &Co, which has already filed MK-3475 in the US to treat advanced melanoma.

  • Chris Bowden joins Agios Chris Bowden joins Agios

    During this time he worked on major cancer medicines, such as melanoma drug Zelboraf (vemurafenib) and Erivedge (vismodegib) for patients with unresectable, locally advanced or metastatic basal cell carcinoma.

More from appointments
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 13 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

Virtual Engagement At Porterhouse: Reflections on the past few months
A look at how the pitfalls of virtual engagement can be avoided and the key advantages of virtual client and KOL engagement strategies in a now predominantly digital world....
July 2020: diversity and inclusion in clinical trials round-up
COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...
Medical Device Clinical Trials 2020
In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...

Infographics